Tissue Repair Ltd (TRP.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.09 (+4.65%) as of
Key statistics
- Market cap
- 5.44M
- Forward P/E
- -1.13
- EPS (TTM)
- -0.0900
- Dividend yield
- 0.00%
- 52-week range
- 0.0550 – 0.4800
- Beta
- 0.22
- Revenue (TTM)
- 2.99M
- Profit margin
- -179.28%
- Volume
- 100.00k
About Tissue Repair Ltd
Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and aesthetic procedure aftercare in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It also develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous leg ulcers; and TR Pro+, a post-procedure gel for the aftercare of acute wounds, and aesthetic and medical procedures. Tissue Repair Ltd was incorporated in 2012 and is based in Chatswood, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Chatswood, NSW, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.